DSIP 2mg (Delta Sleep Inducing Peptide)

Delta sleep-inducing peptide (DSIP) is a nine amino acid peptide that plays various physiological and endocrine roles. It has been associated with altering corticotropin levels, improving sleep patterns, normalizing blood pressure, inhibiting somatostatin secretion, limiting stress, and reducing pain perception. Furthermore, DSIP may have potential applications in the prevention of free radical damage, cancer treatment, and depression.

Properties

• CAS Number: 62568-57-4
• Formula: C₃₅H₄₈N₁₀O₁₅
• Sequence: N-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-C
• Molar Mass:  848.81 g/mol
• Class: Neuropeptide

Benefit

Sleep-Wake Cycle Regulation

DSIP was initially isolated from rabbit brains during slow-wave sleep and has been linked to the regulation of sleep-wake cycles in the central nervous system. The synthesis of DSIP and its specific location within the body remain unknown, but studies have found that DSIP levels are equally high in external tissues as they are in the central nervous system. This suggests that DSIP’s primary function may extend beyond sleep and that it may be produced outside the central nervous system. Animal models indicate that DSIP regulates heart rate, blood pressure, thermogenesis, and the lymphokine system, potentially playing a role in preparing the body for sleep by altering its physiology.

Promotion of Sleep

While research on the mechanism underlying the connection between DSIP and sleep patterns remains conflicting, it is evident that DSIP is related to the onset of sleep. Human studies have shown that DSIP promotes sleep by inducing feelings of sleepiness, shortening sleep onset, and increasing total sleep time by 59% compared to a placebo. However, electroencephalogram (EEG) recordings do not demonstrate sedation, presenting a paradoxical finding. Notably, a significant research study demonstrated that DSIP improved sleep to match that of control subjects in individuals with chronic insomnia. Studies utilizing polysomnographic equipment have revealed that DSIP enhances sleep efficiency.

Potential of DSIP Beyond Sleep Regulation

DSIP is thought to be a hypothalamic hormone with the potential to regulate more than just sleep, similar to how growth hormone influences various aspects of physiology beyond bone and muscle growth. Studies have shown that DSIP restricts the production of somatostatin, a protein produced in muscle cells that inhibits muscle growth. Similar to the effects of GHRP6, DSIP increases growth hormone activity, promoting muscle growth and enlargement. These findings have led researchers to hypothesize that DSIP may have a broader regulatory role in human physiology, extending beyond sleep promotion.

DSIP RESEARCH AND METABOLISM
Studies on rat models have highlighted that Delta Sleep-Inducing Peptide may help change stress-related metabolic fluctuations, which causes mitochondria to switch from oxygen-dependent to oxygen-independent respiration. The latter is less efficient and brings about toxic metabolic byproduct formation. Delta Sleep-Inducing Peptide may promote oxidative phosphorylation even in hypoxic conditions and can thus be beneficial in stroke or heart attack. It appears to assist normal metabolic function and thus reverses the damage caused by oxygen deprivation, protecting tissues until blood flow is restored. Delta Sleep-Inducing Peptide research suggests that DSIP may be a potent anti-oxidant preventing free radical formation and may also be used as an anti-aging supplement.

DSIP and Pain Perception and Relief

Research in rats suggests that DSIP may activate opioid receptors, resulting in a dose-dependent reduction in pain sensations. While opioids and DSIP act on the same receptors in the central nervous system (CNS), DSIP does not induce the same level of dependency associated with opioid medications. A preclinical trial in humans demonstrated that DSIP significantly reduced pain perception and improved mood. Additionally, DSIP exhibited the ability to mitigate pain rebound and other withdrawal symptoms that often occur after discontinuing long-term pain therapy, indicating its potential usefulness in patients who are physiologically dependent on other pain medications.

DSIP Potential in Cancer Prevention

While most cancer research focuses on treatment after diagnosis, there is growing interest in preventive strategies. Cancer vaccines aim to eliminate cancerous cells by stimulating the body’s immune system. In mouse studies, DSIP has shown promise as a potential preventive measure for cancer. Mice injected with DSIP on a consistent monthly basis demonstrated a 2.6 times lower tumor development rate and a 22.6% decrease in chromosomal defects in bone marrow. These findings suggest that DSIP may be more effective in preventing cancer compared to existing vaccines.

Disclaimer

The information provided above is not intended to substitute medical advice, diagnosis, or treatment. Should you have any questions regarding a medical condition, seek the advice of your physician or a qualified healthcare provider. In no case should medical advice be disregarded or delayed because of what you have read or seen. We bear no responsibility or liability for your use of any of our research compounds and products. Please note that they are being sold for research purposes ONLY. We do NOT condone any personal use.